3 registrations that name reishi mushroom as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 3 registrations
Status
Phase
1US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 3 registrations
RecruitingNCT07294482
The Effects on Sleep Quality of 1:4 Reishi Liquid Extract
No phase
Efforia, Inc
About 100 people
Started Sep 10, 2025
In plain words A study of reishi mushroom in people 18 and older, run by Efforia, Inc. It plans to enroll about 100 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older; healthy volunteers accepted. Conditions: Sleep.
Can read and understand English.
US resident.
Willing and able to follow the requirements of the protocol.
The exclusion criteria are on the listing.
What it tests, as registered
Bristol Fungarium's 1:4 Reishi Mushroom Tincture
Registered summary
Examining the effects of 1ml of Reishi mushroom extract (1:4 extraction ratio, two hot water extractions and an alcohol extraction), taken daily, 30 mins before bed on perceived sleep quality and stress levels. Sleep quality includes: duration, sleep onset latency, nighttime wakings, and perceived restfulness. And consequently, the potential for increased daytime energy levels and a reduction in perceived stress levels.
Where, as registered
1 US site in 1 state.
RecruitingNCT06739720
RCT of Efficacy and Safety of CP003 on CFS/ME or Post COVID-19 Fatigue
Phase 2 and 3
The University of Hong Kong
About 130 people
Started Jan 2, 2025
In plain words A Phase 2 and 3 study of reishi mushroom in people 40 to 60, run by The University of Hong Kong. It plans to enroll about 130 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 40 to 60. Conditions: Chronic Fatigue Syndrome (CFS); Post-COVID ME/CFS.
Meet the Fukuda diagnostic definition of CFS/ME or have persisting fatigue after the infection of SARS-CoV-2
Are able to complete a 6-week course of intervention;
Able to complete the online validated fatigue surveys.
The exclusion criteria are on the listing.
What it tests, as registered
LingZhi capsule
Registered summary
The goal of this clinical trial is to test if a Lingzhi supplement (CP003) helps people with chronic fatigue or post-COVID fatigue feel better. It will also check if the supplement is safe to use. The main questions it aims to answer are: Does the Lingzhi supplement reduce fatigue symptoms? Is it safe to take? How does it affect the body's immune system and inflammation? The investigators will compare people taking the Lingzhi supplement to those who do not receive any treatment (waitlist group) to see if it works. The full summary is on the listing.
Where, as registered
No US site; Hong Kong (1).
RecruitingNCT07534241
Hepatoprotective Effects of Reishi Mushroom- (Ganoderma Lucidum) Among Metabolic Dysfunction-associated Fatty Liver Disease Patients
No phase
University of Lahore
About 102 people
Started Oct 2, 2025
In plain words A study of reishi mushroom in people 35 to 65, run by University of Lahore. It plans to enroll about 102 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 35 to 65; healthy volunteers accepted. Conditions: Lipid Profile; Liver Biomarkers.
Adults aged 35-65 years
BMI between 18.5 and 30 kg/m².
Complete Blood Count test ranges, WBC < 4,000-11,000 cells/µL, RBC Men < 4.5-6.0 / Women 4.0-5.5 million/µL, Hemoglobin: Men < 13.5-17.5 / Women 12.0-15.5 g/dL, Platelets < 150,000-450,000 cells/µL.
Lipid profile test markers (elevated LDL, total cholesterol, or triglycerides less than 150mg/dL high 200-499mg/dL and 500 mg/dL are above high.
3 more inclusion criteria and the exclusion criteria are on the listing.
This 12-week RCT investigates the hepatoprotective and immunomodulatory effects of Ganoderma lucidum combined with a probiotic-rich diet in adults with MAFLD, assessing liver enzymes, lipid profile, inflammation, gut microbiota, and oxidative stress. Findings are expected to show dose-dependent improvements in hepatic fat, insulin resistance, and inflammatory markers, potentially reducing reliance on pharmacotherapy in